ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2024-05-01 DOI:10.1097/WNF.0000000000000590

Pinar Aydogan Avşar, Merve Akkuş

{"title":"ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder.","authors":"Pinar Aydogan Avşar, Merve Akkuş","doi":"10.1097/WNF.0000000000000590","DOIUrl":null,"url":null,"abstract":"Objective: There are limited studies in the literature on the relationship between intestinal and blood-brain barrier permeability and the etiology of schizophrenia. We hypothesized that the difference in serum ZO-1 levels in patients with schizophrenia may affect the severity of the disease. The aim of this study was to investigate the role of changes in serum ZO-1 concentrations in the etiopathogenesis of patients with schizophrenia.Methods: A total of 46 patients, 34 with schizophrenia, 12 with a first psychotic attack, and 37 healthy controls, were included in the study. Symptom severity was determined by applying the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Serum ZO-1 levels were measured from venous blood samples.Results: Serum ZO-1 levels were higher in patients with psychotic disorder compared to healthy controls. There was no statistically significant difference between the groups in the first psychotic attack group and the schizophrenia patients. There was a statistically significant positive correlation between serum ZO-1 levels and Positive and Negative Syndrome Scale positive symptom score.Conclusions: These findings regarding ZO-1 levels suggest that dysregulation of the blood-brain barrier in psychotic disorder may play a role in the etiology of the disorder.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 3","pages":"67-71"},"PeriodicalIF":0.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000590","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: There are limited studies in the literature on the relationship between intestinal and blood-brain barrier permeability and the etiology of schizophrenia. We hypothesized that the difference in serum ZO-1 levels in patients with schizophrenia may affect the severity of the disease. The aim of this study was to investigate the role of changes in serum ZO-1 concentrations in the etiopathogenesis of patients with schizophrenia.

Methods: A total of 46 patients, 34 with schizophrenia, 12 with a first psychotic attack, and 37 healthy controls, were included in the study. Symptom severity was determined by applying the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Serum ZO-1 levels were measured from venous blood samples.

Results: Serum ZO-1 levels were higher in patients with psychotic disorder compared to healthy controls. There was no statistically significant difference between the groups in the first psychotic attack group and the schizophrenia patients. There was a statistically significant positive correlation between serum ZO-1 levels and Positive and Negative Syndrome Scale positive symptom score.

Conclusions: These findings regarding ZO-1 levels suggest that dysregulation of the blood-brain barrier in psychotic disorder may play a role in the etiology of the disorder.

查看原文本刊更多论文

ZO-1血清水平作为精神障碍的潜在生物标记物

研究目的关于肠道和血脑屏障通透性与精神分裂症病因之间关系的文献研究有限。我们假设，精神分裂症患者血清 ZO-1 水平的差异可能会影响疾病的严重程度。本研究旨在探讨血清 ZO-1 浓度变化在精神分裂症患者发病机制中的作用：研究共纳入 46 名患者，其中 34 名精神分裂症患者、12 名首次精神病发作患者和 37 名健康对照组患者。症状严重程度通过应用阳性和阴性综合征量表以及临床总体印象-严重程度量表来确定。通过静脉血液样本测量血清ZO-1水平：结果：与健康对照组相比，精神障碍患者的血清 ZO-1 水平较高。首次精神病发作组和精神分裂症患者组之间的差异无统计学意义。血清ZO-1水平与阳性和阴性综合征量表阳性症状评分之间存在统计学意义上的显著正相关：这些有关 ZO-1 水平的研究结果表明，精神障碍患者血脑屏障的失调可能是该疾病的病因之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.